Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Increased Cypher Shipments Unhindered By Cordis Warning Letter – J&J Exec

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson will ramp up inventory of the Cypher sirolimus-eluting stent to fulfill existing back-orders over the next several weeks

You may also be interested in...



Cordis Recalls 300 Underweight Cypher Units, Predicts Zero Adverse Events

Johnson & Johnson/Cordis' 300-unit recall of its Cypher sirolimus-eluting stent from 145 centers nationwide marks the most recent manufacturing glitch for the high-profile sector

Cordis Recalls 300 Underweight Cypher Units, Predicts Zero Adverse Events

Johnson & Johnson/Cordis' 300-unit recall of its Cypher sirolimus-eluting stent from 145 centers nationwide marks the most recent manufacturing glitch for the high-profile sector

Boston Scientific Taxus Japan Launch Delayed Until Second Half Of 2006

Boston Scientific will begin a required Japanese premarket approval trial next year for its Taxus paclitaxel-eluting stent, incorporating a short-term endpoint of major adverse coronary events (MACE)

Related Content

UsernamePublicRestriction

Register

MT021039

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel